I just received the 'good' news that my Oncotype DX Recurrence Score is 20. As I'm >50 years of age (54), there is no Chemotherapy Benefit (<1%). The most effective treatment will be endocrine therapy following radiotherapy. I still have an intermediate risk of recurrence and I am still worried about that, of course, but now I know that putting myself through chemo would have been of little benefit. If the report had recommended chemotherapy, I would have gone forward with confidence that the benefits outweigh the side-effects.
Therefore, I conclude that the expense ($5000) of the Oncotype DX genomic assay is well worth it.
My medical oncologists said they advocate for the test to be covered by the
Pharmaceutical Benefits Scheme (PBS).
They want patients/the public to advocate for Oncotype DX too.
How do we go about that? I was able to afford it (just), but I would like everyone who is a suitable candidate to be able to access the test. In the long term, it would spare many people from having chemo unnecessarily - and spare the public health system the expense of chemo and the cost of dealing with subsequent health issues.
The Oncotype DX breast cancer assay can be used by all patients newly diagnosed with early stage, invasive breast cancer who are: